Indeed, LY treatment significantly reduced the phosphorylation of T220/T179, irrespective of Smad2/3 activation, but had negligible effects on the other linker serine residues in both hESC and tumour cell lines (Fig. 4b–d; Supplementary Fig. 4a–e). Here, SMAD2 is linked to neoplasm.